• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec11
Mesoblast Limited Announces Remestemcel-L Superiority Over Ruxolitinib in Treating SR-aGvHD
23:22
Nov5
Mesoblast's Chronic Lower Back Pain Phase III Study Data to be Discussed by FDA
00:02
Oct22
Mesoblast Limited Reports Ryoncil® Sales Growth and Plans for Key Trials
10:37
Oct8
Analyst McCarthy Gives Mesoblast Strong Buy Rating
16:21
Oct7
Shapiro Recommends Mesoblast Limited in Healthcare Sector
05:06
Oct6
Mesoblast Limited Reports 66% Growth in Ryoncil® Sales to $21.9 Million
23:26

Schedules & Filings

Schedules
Filings
Aug28
Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 7.021 M, Net Income -27.1 M, EPS -0.2128

Feb26
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.578 M, Net Income -23.97 M, EPS -0.21

Aug28
Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 1.257 M, Net Income -27.71 M, EPS -0.2523

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More